HighPoint Buys 1,271 Shares in Align Technology, Others Followby Lilu Anderson 21.06.2024"HighPoint Advisor Group invests in Align Tech, joining other major investors. Analysts offer a moderate buy rating with potential future ...
Bidders Line Up for HSBC’s German Fund Units: Sourcesby Mark Eisenberg 21.06.2024HSBC's fund administration and custody units in Germany attract bidders like State Street, BNP Paribas, and Caceis, with valuations over ...
South Pasadena’s City Finance Crisis: What You Need to Knowby Mark Eisenberg 21.06.2024Explore South Pasadena's financial crisis, leadership crossroads, and upcoming critical decisions on budget and appropriations in this detailed article.
Apple-Affirm Deal Could Boost GMV by 35%, Says Mizuhoby Mark Eisenberg 21.06.2024"Mizuho analysis: Apple-Affirm partnership could boost BNPL volume by 35%, adding $12 billion by FY25, potentially justifying Affirm's stock surge."
Fortress Biotech Sees Upgrades Amid Investor Shiftsby Lilu Anderson 20.06.2024"Fortress Biotech (FBIO) upgraded to 'Hold' by StockNews.com amid 5.8% decline; analysts offer mixed ratings as hedge funds increase stakes."
Nutanix CFO Sells Over $668K in Stock; Acquires RSUsby Mark Eisenberg 20.06.2024Nutanix CFO Duston Williams sells $668,787 in stock; insights into his trading activities and company’s robust financials, growth, and market ...
Ferrellgas Partners Q3: Navigating Weather Impacts, Adding Accountsby Mark Eisenberg 20.06.2024Ferrellgas Partners reports mixed Q3 results: revenue drop, gross profit decrease, Blue Rhino's EBITDA grows by 19%, and explores debt ...
Morgan Stanley Upgrades ASM International Stock to Overweightby Mark Eisenberg 20.06.2024Morgan Stanley upgrades ASM International to Overweight, raises target to €800, citing strong AI-driven growth and increased order momentum.
Cognyte Q1: Robust Results & Upgraded FY2025 Forecastby Mark Eisenberg 19.06.2024Cognyte reports a strong Q1 FY2025 with $83M revenue, 13% growth; raises FY2025 outlook to $344M, focusing on AI-driven solutions ...
Trinity Biotech Stock Rated “Buy” Amid Price Fluctuationsby Lilu Anderson 19.06.2024Trinity Biotech plc gets a "buy" rating from StockNews.com analysts, spotlighting potential for investors with a focus on its diagnostic ...